This year’s JPMorgan confab, the first since covid’s chilling effect on such gatherings, was full of energy and enthusiasm. But it was also marked by questions about the future of health care investment.
As flexible treatment options spurred by the covid pandemic wane, patients relying on medications classified as controlled substances worry that without action to extend the loosened rules, it’ll be harder to get their meds.
For contact tracers of sexually transmitted infections, telephones and text messages have become ineffective. Dating apps increasingly are their best bet for informing people of their exposure risks.
Veterans Affairs’ electronic health records aren’t friendly to blind- and low-vision users, whether they’re patients or employees. It’s a microcosm of America’s health care system.
Work-based benefits may expand access to abortion for people who live in areas where the service is unavailable, but experts warn that claiming benefits could create a paper trail for law enforcement officials to follow.
The interest, and investment, in coaching and encouragement is a curious turn for an industry that likes to boast of its billion-dollar pills and sophisticated artificial intelligence.
Russia’s attacks on Ukraine are making it harder for the health care system to secure important supplies, including gases used in imaging and by dentists.
Health data can be shockingly available. A group of nonprofits and corporations is proposing to patch up the holes in health apps, but many of the biggest companies didn’t participate in the proposal’s creation.